Roberto E Favoni
Overview
Explore the profile of Roberto E Favoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pattarozzi A, Carra E, Favoni R, Wurth R, Marubbi D, Filiberti R, et al.
Stem Cell Res Ther
. 2017 May;
8(1):119.
PMID: 28545562
Background: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after cytotoxic drug treatment is responsible...
2.
Thellung S, Favoni R, Wurth R, Nizzari M, Pattarozzi A, Daga A, et al.
Curr Drug Targets
. 2015 Aug;
17(7):824-49.
PMID: 26240051
Malignant pleural mesothelioma (MPM) is one of the deadliest and most heterogeneous tumors, highly refractory to multimodal therapeutic approach, including surgery, chemo- and radiotherapy. Preclinical and clinical studies exploring the...
3.
Carra E, Barbieri F, Marubbi D, Pattarozzi A, Favoni R, Florio T, et al.
Cell Cycle
. 2013 Jan;
12(3):491-500.
PMID: 23324350
Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis. We investigated the effects of the multi-kinase inhibitor sorafenib on six cultures isolated...
4.
Favoni R, Alama A
Drug Discov Today
. 2012 Aug;
18(1-2):11-24.
PMID: 22885521
Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome...
5.
Favoni R, Daga A, Malatesta P, Florio T
Br J Pharmacol
. 2012 Feb;
166(2):532-53.
PMID: 22289125
The incidence of human malignant pleural mesothelioma (hMPM) is still increasing worldwide. hMPM prognosis is poor even if the median survival time has been slightly improved after the introduction of...
6.
Barbieri F, Wurth R, Favoni R, Pattarozzi A, Gatti M, Ratto A, et al.
Biochem Pharmacol
. 2011 Jul;
82(10):1467-77.
PMID: 21787763
Malignant pleural mesothelioma (MPM) is an aggressive chemotherapy-resistant cancer. Up-regulation of epidermal growth factor receptor (EGFR) plays an important role in MPM development and EGFR-tyrosine kinase inhibitors (TKIs) may represent...
7.
Favoni R, Florio T
Trends Pharmacol Sci
. 2011 May;
32(8):463-79.
PMID: 21620489
Human malignant pleural mesothelioma (hMPM) is an aggressive asbestos-associated cancer, the incidence of which is increasing and which, despite progress in diagnosis and therapy, continues to have a poor prognosis....
8.
Pinton G, Thomas W, Bellini P, Manente A, Favoni R, Harvey B, et al.
PLoS One
. 2010 Dec;
5(11):e14110.
PMID: 21124760
Background: The role of estrogen and estrogen receptors in oncogenesis has been investigated in various malignancies. Recently our group identified estrogen receptor beta (ERβ) expression as an independent prognostic factor...
9.
Favoni R, Pattarozzi A, Lo Casto M, Barbieri F, Gatti M, Paleari L, et al.
Curr Cancer Drug Targets
. 2010 Jan;
10(2):176-91.
PMID: 20088784
Altered EGFR activity is a causal factor for human tumor development, including malignant pleural mesotheliomas. The aim of the present study was the evaluation of the effects of Gefitinib on...
10.
Griffero F, Daga A, Marubbi D, Capra M, Melotti A, Pattarozzi A, et al.
J Biol Chem
. 2009 Jan;
284(11):7138-48.
PMID: 19147502
Because a subpopulation of cancer stem cells (tumor-initiating cells, TICs) is believed to be responsible for the development, progression, and recurrence of many tumors, we evaluated the in vitro sensitivity...